johnson & johnsonJohnson & Johnson Recalls Eprex Anemia Drug
Johnson & Johnson is recalling about 200,000 syringes of Eprex, an anemia drug sold wholesale and in pharmacies. Some batches of the drug may not be potent enough, health regulators are warning. The recall affects products in 17 countries, including the U.K and Canada. No adverse events have been tied to the issue, J&J says. The manufacturer assumes that the prefilled syringes have already been used, since they were delivered to the market quite a while ago. There are around …
Federal Prosecutors Want $1 Billion from J&J
Federal prosecutors are demanding that Johnson & Johnson pay about $1 billion to settle an investigation into whether the company marketed antipsychotic drug Risperdal for unapproved uses. The probe started in 2004 with a subpoena demanding documents on J&J’s sales practices, payments to physicians related to the marketing of Risperdal, and clinical trials related to the drug. Marketing drugs for unapproved purposes has become more common in past years, as pharmaceutical companies seek to compete with and outsell their rivals. …
Higher Bleeding Rates Detected in J&J-Bayer Drug
A heart drug from Johnson & Johnson and Bayer AG was recently proven to be effective in preventing certain blood clots—even though it may cause higher bleeding rates that limit the drug’s effectiveness. Patients who received the drug, rivaroxaban, experienced bleeding at more than double the rate of those in a group given an anticoagulant and a placebo, according to a study presented at the American College of Cardiology in New Orleans. Around 8.100 patients participated in the study. Half …
FDA Looking Into Link Between Anemia Drug and Deaths
The U.S. Food and Drug Administration is investigating whether a Johnson & Johnson anemia drug increases the chance of death in stroke patients. A German medical study found that 16 percent of stroke patients treated with the drug, Eprex, died within three months of taking the drug, compared to just nine percent who died after receiving a placebo. Â The study was designed to test whether Eprex might improve brain function in stroke patients, which is an unapproved use of the …
Foot Cream Could Cause Cancer, FDA Warns
The Food and Drug Administration is warning patients that using large amounts of a Johnson & Johnson foot ulcer medication could heighten their risk of cancer. The FDA warning concerned Regranex, which is prescribed to treat severe foot and leg ulcers in diabetics. Patients who used three or more tubes of the foot cream over a 20-month period were five times more likely to die of cancer, the FDA warned. About 750,000 people have used the drug since it was …
facebook
rss
twitter